Alnylam Announces $250 Million Expansion of U.S. RNAi Therapeutics Manufacturing Facility
This video is intended for U.S. audiences On December 17, 2025, Alnylam announced a $250 million expansion of our Norton, Massachusetts (USA) drug manufacturing facility. This investment reflects our commitment to ongoing innovation and the Massachusetts life-sciences ecosystem and will help ensure that RNAi-based medicines will be produced here at scale for the benefit of patients world-wide. Learn more about this investment: https://bit.ly/4jdQXsz and we invite you to learn more about how we make our RNAi therapeutics: https://bit.ly/44GBtHt ALN_NortonGB-2025
▶︎
Alnylam & RNAi Therapeutics: Making our Medicines
▶︎
A Message from Alnylam CEO Yvonne Greenstreet - Reflecting on 2025 and Looking forward to 2026
▶︎
Alnylam Challengers - A Community Impact Program to Improve Health Access in Underserved Communities
▶︎
Marc – Living with Wild-Type ATTR Amyloidosis with Cardiomyopathy
▶︎
Alnylam Challengers: Improving Access to Healthcare in Boston by Investing in Care Navigators
▶︎
RNAi, a promising platform for drug development
▶︎
Physiopathologie de la PHA
▶︎
Alnylam's siRELIS(TM) Enzymatic Ligation Platform
▶︎
Alnylam & RNAi Therapeutics: Making our Medicines
▶︎
Stephanie, Atteinte de PHA
▶︎
Alnylam Act - No Charge, Third Party Genetic Testing & Counseling
▶︎
Ben, Lebt Mit AHP
▶︎